View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 2, 2017updated 13 Jul 2022 10:11am

Concert Pharmaceuticals commences Phase IIa trial to study CTP-543 in alopecia areata

US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata.

CTP-543 was discovered using the firm's deuterium chemistry technology and is an orally administered, selective Janus kinase 1 (JAK 1) and Janus kinase 2 (JAK 2) inhibitor.

The double-blind, randomised, placebo-controlled, parallel-dose Phase IIa trial will assess the safety and efficacy of CTP-543 in up to 100 patients following 12 months of treatment.

The trial will compare twice-daily 4mg, 8mg, 12mg and 16mg doses of CTP-543 with placebo.

Concert Pharmaceuticals president and chief executive officer Roger Tung said: “Alopecia areata is a devastating autoimmune disease that impacts half a million or more patients in the US at any given time.

“We intend to be at the forefront of advancing a new oral treatment for alopecia areata patients and look forward to assessing CTP-543’s therapeutic efficacy in the Phase II trial.”

"We intend to be at the forefront of advancing a new oral treatment for alopecia areata patients and look forward to assessing CTP-543’s therapeutic efficacy in the Phase II trial."

During the trial, the primary analysis will be performed at week 24 and conducted using the severity of alopecia tool (SALT).

An additional CTP-543 dosing for a period of 28 weeks will also be included for all the participating patients.

The top-line results from the trial are expected to be reported in the first quarter of next year.

The results from Phase I trials of CTP-543 conducted in healthy volunteers showed that the product was well tolerated without serious adverse events and demonstrated enhanced exposure with increasing doses.


Image: Patient suffering from patchy hair loss due to alopecia areata. Photo: courtesy of Carolyn P Speranza.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena